These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 487820)

  • 1. The protective influence of progestogen only contraception against vaginal moniliasis.
    Toppozada M; Onsy FA; Fares E; Amir S; Shaala S
    Contraception; 1979 Aug; 20(2):99-103. PubMed ID: 487820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Cyclofem in the treatment of depot medroxyprogesterone acetate induced amenorrhea.
    Piya-Anant M; Koetsawang S; Patrasupapong N; Dinchuen P; d'Arcangues C; Piaggio G; Pinol A
    Contraception; 1998 Jan; 57(1):23-8. PubMed ID: 9554247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depo-Provera in the treatment of recurrent vulvovaginal candidiasis.
    Dennerstein GJ
    J Reprod Med; 1986 Sep; 31(9):801-3. PubMed ID: 2945926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
    Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone density among long-term users of medroxyprogesterone acetate as a contraceptive.
    Paiva LC; Pinto-Neto AM; Faundes A
    Contraception; 1998 Dec; 58(6):351-5. PubMed ID: 10095971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timing of onset of contraceptive effectiveness in Depo-Provera users. II. Effects on ovarian function.
    Petta CA; Faúndes A; Dunson TR; Ramos M; DeLucio M; Faúndes D; Bahamondes L
    Fertil Steril; 1998 Nov; 70(5):817-20. PubMed ID: 9806559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Return of fertility after discontinuation of depot medroxyprogesterone acetate and intra-uterine devices in Northern Thailand.
    Pardthaisong T; Gray RH; McDaniel EB
    Lancet; 1980 Mar; 1(8167):509-12. PubMed ID: 6102234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Contraception with injectable long-acting preparation depo-provera].
    Prilepskaia VN; Kondrikov NI; Tagieva TT
    Akush Ginekol (Mosk); 1995; (3):7-10. PubMed ID: 7653732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone density in long term users of depot medroxyprogesterone acetate.
    Gbolade B; Ellis S; Murby B; Randall S; Kirkman R
    Br J Obstet Gynaecol; 1998 Jul; 105(7):790-4. PubMed ID: 9692421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding in women using depot medroxyprogesterone acetate for contraception. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-acting Systemic Agents for Fertility Regulation.
    Said S; Sadek W; Rocca M; Koetsawang S; Kirwat O; Piya-Anant M; Dusitsin N; Sethavanich S; Affandi B; Hadisaputra W; Kazi A; Ramos RM; d'Arcangues C; Belsey EM; Noonan E; Olayinka I; Pinol A
    Hum Reprod; 1996 Oct; 11 Suppl 2():1-13. PubMed ID: 8982739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Food and Drug Administration and medroxyprogesterone acetate. What are the issues?
    Rosenfield A; Maine D; Rochat R; Shelton J; Hatcher RA
    JAMA; 1983 Jun; 249(21):2922-8. PubMed ID: 6221125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WHO special programme of research, development and research training in human reproduction. Task force on long-acting agents for the regulation of fertility.
    Contraception; 1982 Jan; 25(1):1-11. PubMed ID: 6460593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing changes in vaginal bleeding patterns in contracepting women.
    Machin D; Farley TM; Busca B; Campbell MJ; d'Arcangues C
    Contraception; 1988 Aug; 38(2):165-79. PubMed ID: 2971504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Some effects of depo-medroxyprogesterone acetate (DMPA): observations in the nursing infant and in the long-term user.
    Dahlberg K
    Int J Gynaecol Obstet; 1982 Feb; 20(1):43-8. PubMed ID: 6126406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association of depo-medroxyprogesterone acetate and breast cancer.
    Greenspan AR; Hatcher RA; Moore M; Rosenberg MJ; Ory HW
    Contraception; 1980 Jun; 21(6):563-9. PubMed ID: 7428364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depression in users of depo-medroxyprogesterone acetate.
    Westhoff C; Wieland D; Tiezzi L
    Contraception; 1995 Jun; 51(6):351-4. PubMed ID: 7554975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum high density lipoprotein cholesterol levels in women using a contraceptive injection of depot-medroxyprogesterone acetate.
    Kremer J; de Bruijn HW; Hindriks FR
    Contraception; 1980 Oct; 22(4):359-67. PubMed ID: 7449384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case for concern?
    Gartland A
    Nurs Times; 1983 May 4-10; 79(18):10-1. PubMed ID: 6222288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contraception with an injectable progestin. A study of its use in postpartum women.
    Mishell DR; el-Habashy MA; Good RG; Moyer DL
    Am J Obstet Gynecol; 1968 Aug; 101(8):1046-53. PubMed ID: 5663345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaginal bleeding disturbances associated with the discontinuation of long-acting injectable contraceptives. From the World Health Organization Special Programme for Research, Development, and Research Training in Human Reproduction; Task Force on Long-acting Systemic Agents for the Regulation of Fertility.
    Gray RH; Parker RA; Diethelm P
    Br J Obstet Gynaecol; 1981 Mar; 88(3):317-21. PubMed ID: 7008825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.